peptides vs glp 1 Semaglutide Tirzepatide Peptides semaglutide: what this GLP-1
Description
Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural phenomenon.
Abnormalities of the incretin axis have been implicated in the pathogenesis of type 2 diabetes mellitus
Well, thats exactly what happened with the GLP-1 receptor agonists
The glp-1 agonists market is expected to reach US$ 118,926.1 billion by 2032, growing at a significant CAGR of 18.1% from 2026 to 2032.
Emerging applications include non-alcoholic fatty liver disease and neurodegenerative conditions
In clinical trials, GLP-1 RAs were shown to significantly lower blood pressure (BP) in addition to HbA1c and body weight (BW), indicating the possibility as anti-hypertensive medication of type 2 DM individuals
